WeVote
Log In

Bill

Bill

H 2223

An Act relative to benzodiazepines and non-benzodiazepine hypnotics

194th Legislature (2025-2026) Introduced by Mike Kushmerek and 1 co-sponsor

Massachusetts legislation regulates benzodiazepine and sedative-hypnotic prescribing to reduce addiction risks while balancing access for patients with legitimate medical needs.

Hearing scheduled for 11/10/2025 from 01:00 PM-05:00 PM in A-2
0
WeVote Research Nonpartisan
Bill Summary · H 2223

Legislative bill overview

H 2223 addresses the regulation and use of benzodiazepines and non-benzodiazepine hypnotics (sedative-hypnotic medications like Ambien) in Massachusetts. The bill likely aims to implement prescribing guidelines, monitoring protocols, or restrictions on these controlled substances given their high potential for dependence and abuse.

Why this is important

Benzodiazepines and Z-drugs (non-benzodiazepine hypnotics) are among the most frequently misused prescription medications, with significant risks including overdose, addiction, falls, and cognitive impairment—particularly in older adults. Massachusetts, like many states, has faced opioid and prescription drug abuse crises, making medication safety legislation a public health priority.

Potential points of contention

  • Patient access vs. addiction prevention: Stricter prescribing limits could benefit some patients but may restrict treatment options for those with legitimate anxiety or insomnia disorders who benefit from these medications
  • Duration and dosage caps: Requirements for lower doses or shorter treatment periods could conflict with evidence-based medical practice for certain conditions requiring longer-term therapy
  • Healthcare provider burden: New monitoring, documentation, or prescription database requirements may increase administrative costs and complexity for prescribers while potentially improving safety oversight

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.